Abstract
A 36-year-old woman who was undergoing dialysis for end-stage kidney disease (ESKD) was admitted to our hospital with consciousness disorder. She was diagnosed with Budd–Chiari syndrome due to antiphospholipid syndrome at the age of 28 years. Her kidney function and leg edema gradually deteriorated. After initiation of hemodialysis (HD), transient loss of consciousness due to hepatic encephalopathy during HD treatment occurred frequently. Her kidney replacement therapy was changed to online hemodiafiltration (HDF), which dramatically improved her hepatic coma. Compared with HD, HDF contributed to the increase in Fischer’s ratio and decrease in tryptophan level, which has a high protein-bound property. This case suggests that HDF may be beneficial for hepatic encephalopathy in ESKD patients by modulating the amino acid profile.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Munoz SJ. Hepatic encephalopathy. Med Clin North Am. 2008;92(4):795–812.
Lornoy W, Becaus I, Billiouw JM, Sierens L, Van Malderen P, D’Haenens P. On-line haemodiafiltration. Remarkable removal of beta2-microglobulin. Long-term clinical observations. Nephrol Dial Transplant. 2000;15(Suppl 1):49–54.
Masakane I. How to prescribe hemodialysis or hemodiafiltration in order to ameliorate dialysis-related symptoms and complications. Contrib Nephrol. 2011;168:53–63.
Nakai S, Iseki K, Tabei K, et al. Outcomes of hemodiafiltration based on Japanese dialysis patient registry. Am J Kidney Dis. 2001;38(4 Suppl 1):S212–6.
Shinzato T, Maeda K. Push/pull hemodiafiltration. Contrib Nephrol. 2007;158:169–76.
Matsubara S, Okabe K, Ouchi K, et al. Continuous removal of middle molecules by hemofiltration in patients with acute liver failure. Crit Care Med. 1990;18(12):1331–8.
Pavri TM, Herbst A, Reddy R, Forde KA. Budd–Chiari syndrome: a single-center experience. World J Gastroenterol. 2014;20(43):16236–44.
Wilkey D, Yocum DE, Oberley TD, Sundstrom WR, Karl L. Budd–Chiari syndrome and renal failure in Behcet disease. Report of a case and review of the literature. Am J Med. 1983;75(3):541–50.
Sinico RA, Cavazzana I, Nuzzo M, et al. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol. 2010;5(7):1211–7.
Rysava R, Zabka J, Peregrin JH, Tesar V, Merta M, Rychlik I. Acute renal failure due to bilateral renal artery thrombosis associated with primary antiphospholipid syndrome. Nephrol Dial Transplant. 1998;13(10):2645–7.
Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol. 1999;10(3):507–18.
Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35.
Moriwaki H, Shiraki M, Iwasa J, Terakura Y. Hepatic encephalopathy as a complication of liver cirrhosis: an Asian perspective. J Gastroenterol Hepatol. 2010;25(5):858–63.
Park CH, Joo YE, Kim HS, Choi SK, Rew JS, Kim SJ. Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient. J Korean Med Sci. 2005;20(1):150–2.
Nishimoto Y, Hoshino H, Sato S, et al. Extrahepatic portosystemic venous shunt without portal hypertension. Intern Med. 1997;36(12):886–9.
Ueda M, Kojima C, Sugiura H, et al. Hyperammonemia with intermittent loss of consciousness caused by chronic portal-systemic shunt encephalopathy (CPSE) in hemodialysis patient—a case report. J Jpn Soc Dial Ther. 2007;40(5):445–50.
Ubara Y, Hoshino J, Tagami T, et al. Hemodialysis-related portal-systemic encephalopathy. Am J Kidney Dis. 2004;44(3):e38–42.
Paraiso V, Francos M, Rodriguez-Berzosa F, et al. Portosystemic encephalopathy in a patient treated with peritoneal dialysis. Am J Kidney Dis. 2007;49(6):854–8.
Hida M, Suzuki H, Kitamura M. Efficacy of hemodiafiltration for hemodialysis patients with liver cirrhosis. Jpn J Artif Organs. 1999;28(1):134–7
Pardridge WM. Blood–brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem Res. 1998;23(5):635–44.
Saleem DM, Haider S, Khan MM, Shamsi T, Haleem DJ. Role of tryptophan in the pathogenesis of hepatic encephalopathy. J Pak Med Assoc. 2008;58(2):68–70.
Tamura K, Takagi N, Yamaguchi S, et al. A case of hepatic coma with chronic renal failure on hemodialysis: successful treatment with hemodiafiltration. J Jpn Soc Dial Ther. 1994;27(6):997–1001.
Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol. 1993;4(5):1205–13.
Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347(25):2010–9.
Ookawara S, Saitou M, Suzuki M, Yahagi T, Tabei K, Asano Y. Changes in circulating plasma volume as a marker of dry weight in chronic hemodialyzed patients. J Jpn Soc Dial Ther. 1999;32(7):1051–7.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that no conflict of interest exists.
About this article
Cite this article
Wakamatsu, T., Yamamoto, S., Kamimura, K. et al. Hemodiafiltration for hepatic encephalopathy induced by Budd–Chiari syndrome in a patient with end-stage kidney disease. CEN Case Rep 5, 125–130 (2016). https://doi.org/10.1007/s13730-015-0209-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13730-015-0209-7